Contracts expiring soon — NAICS 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
When a federal contract hits its end date, the agency usually buys the same thing again — and the rebid is open to anyone. These are the Research and Development in Biotechnology (except Nanobiotechnology) contracts coming up for renewal, soonest first.
529 contracts on the radar — page 10 of 11
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PROVE A METHODOLOGY TO MEASURE DOSE IN A PHANTOM SUCH THAT THERE WILL BE RESULT NIST TRACEABLE DOSE HARMONIZATION AMONG INSTITUTIONS. INCLUDED IN THIS ACTIVITY WILL BE A MEASURE OF THE RADIATION FIELD USIN
THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI
DESIGN, DEVELOPMENT, AND TESTING OF GROUND AND FLIGHT UNIT(S) AS WELL AS COMPLETION OF FLIGHT DEMONSTRATION(S) ON THE ISS NATIONAL LAB (NL) OR A CLD OR OTHER LEO ORBITAL PLATFORM.
LABORATORY ASSAY FOR TRAUMATIC BRAIN INJURY
REPURPOSING OF A FERRIC IRON-CONTAINING HEME B COMPLEX (PANHEMATIN) AND A SULFANE SULFUR-LINKED DITHIOCARBAMATE (DISULFIRAM) AS POTENTIAL MCMS AGAINST KNOCKDOWN AGENTS
PREFLIGHT PROJECT GOAL IS TO PROVIDE THE REQUIRED PREFLIGHT TESTS TO SUPPORT THE AVATAR FLIGHT PROJECT FOR ITS ARTEMIS II MISSION.
DR. WEINER STUDY OF CONTEXTUAL ERRORS IN MEDICAL DECISION MAKING WITH THE UNIVERSITY OF ILLINOIS - CHICAGO
INTEGRASE INHIBITOR LAT FLOW DEVICES - EO 14398
SERVICES TO COLLECT NEXT-GENERATION SEQUENCING DATA FOR GENOME SKIMMING, POPULATION STRUCTURE, AND RELATED GENOMIC DATA NEEDS IN MANAGEMENT-RELEVANT MARINE SPECIES.
RESEARCH AND DEVELOPMENT
RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]).
PHASE II SBIR ROBUST OPERATIONAL ULTRA-HIGH THROUGHPUT CELL LINEAGE TRACKING FOR RAPID BIOENGINEERING AND PATHOGEN DETECTION
THIS IS A NEW PURCHASE ORDER FOR INTERNATIONAL COMMITTEE FOR INFORMATION TECHNOLOGY STANDARDS (INCITS) MEMBERSHIP.
LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESPIRATORY DISTRESS
CHEM 2207- EVALUATION OF LYOPHILIZED ELAPID VENOM ACETYLCHOLINESTERASE AND GLYCOPYRROLATE VERSUS CRITERION STANDARD TREATMENT ON NERVE AGENT MORTALITY (ELEVATE CST STUDY)
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE BIOFIRE EMERGING COV PANEL AS A NUCLEIC ACID AMPLIFICATION TEST PANEL FOR USE ON THE EASY-TO-USE FILMARRAY 2.0 AND FILMARRAY TORCH PLATFORMS.
THE OVERARCHING OBJECTIVE IS TO ESTABLISH A QUANTITATIVE IN VITRO IN VIVO EXTRAPOLATION FRAMEWORK CAPABLE OF PREDICTING THE INFLUENCE OF FORMULATION COMPOSITION, DIGESTION BEHAVIOR, CHYLOMICRON BINDING, AND PRANDIAL STATE ON DRUG BIOAVAILABILITY AND
EO 14398-BROAD AGENCY ANNOUNCEMENT (BAA) CONTRACT FOR MODERNIZING OUTCOME DATA FOR OPIOID USE DISORDER (MOD-OUD)
FEASIBILITY STUDY OF FLYING ORGANOIDS IN LEO USING THE SAME PAYLOAD MODEL AS FLOWN ON ARTEMIS II.
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO
ACE RAPID MOLECULAR TEST SYSTEM FOR POINT OF CARE (POC) AND IN-HOME USE WITH SALIVA AND SWAB SAMPLES FOR COVID-19 AND BEYOND
NICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE
NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE
OT TASK ORDER 5
NICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE
ADIPOSE TISSUE MECHANOSENSING IN TRUE MICROGRAVITY (PDR THROUGH FLIGHT)
RESEARCH AND DEVELOPMENT
NICHD:R&D:CENTRAL LABORATORY FOR A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION:NON-SEVERABLE
CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, MEDETOMIDINE, AND OTHER ?2 AGONISTS
NICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE
NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: SEVERABLE
NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE
NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY
SWITCH PROGRAM (ICCG) BASE
THERAPEUTIC TESTING IN MURINE MODELS OF FUNGAL INFECTIONS
RASP WILL DEVELOP ENHANCED RADAR SP CAPABILITIES THAT TAKE ADVANTAGE OF NEXT GENERATION RECEIVERS/EXCITERS AND COMPUTING ACCELERATORS FOR TRANSITION INTO SHIPBOARD RADARS THAT OPERATE IN INCREASINGLY HARSH ENVIRONMENTS AGAINST CHALLENGING TARGETS
DEVELOPMENT OF ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR NINDS NIH BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROJECT
RESEARCH AND DEVELOPMENT FOR IN-SPACE PRODUCTION CONCEPTS OF NANOBIOREACTOR MODELS. THIS WAS AWARDED OFF OF THE NASA RESEARCH ANNOUNCEMENT NNJ13ZBG001N. NOTE THAT "BASIC RESEARCH" IS NOT A SELECTABLE SOLICITATION TYPE FOR PURCHASE ORDERS IN FPDS.
BIOLOGICAL TECHNOLOGIES OFFICEWIDE
TO DEVELOP AND CONDUCT 3D CORRELATIVE IMAGING, QUANTITATIVE AI-BASED ANALYSIS OF CRITICAL QUALITY ATTRIBUTES (CQAS), AND PERFORM IMAGE- BASED IN SILICO RELEASE MODELLING, USING MODEL LONG-ACTING DRUGS, INHALATION PRODUCTS, AND TOPICAL PRODUCTS.
RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]).
SUBAGREEMENTS & FLOW-THRU - WRAIR
SUBAGREEMENTS & FLOW-THRU - USAISR
SUBAGREEMENTS & FLOW-THRU - USAMRIID
ADMINISTRATIVE PROGRAM COSTS - USAMRDC
ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.
LEVERAGING IKRAPH FOR PERSONALIZED NUTRITION PLANNING IN CANCER PREVENTION AND MANAGEMENT
LEVERAGING THE GUT MICROBIOME AS AN INTEGRATOR OF NUTRITIONAL STATUS: A FEASIBILITY STUDY OF MICROBIOME NUTRITIONAL DIAGNOSTICS (MINU-DX)
BAA BENEFIT-TRANSFER METHODS ON DIABETES MEDICAL DEVICES FY24C1IP2 DPCD
NONCLINICAL SERVICES FOR THE DEVELOPMENT OF INTERVENTIONAL AGENTS FOR INFECTIOUS DISEASES
See your codes' radar every morning.
Subscribers get this same radar filtered to their exact NAICS codes in the daily digest — plus every new open bid that matches. Start your 14-day trial →